Switching To or From Prolia (Denosumab): Patient Reports, Clinical Evidence, and What to Expect

Denosumab is a monoclonal antibody that blocks RANKL, a protein needed for osteoclasts to break down bone. It is sold under two brand names for two different uses and two different doses: Prolia, 60 mg by subcutaneous injection every six months, FDA-approved for osteoporosis in postmenopausal women at high fracture risk (and some other bone-loss indications on the label); and Xgeva, 120 mg subcutaneous monthly, used for cancer-related bone complications. This article is about Prolia and about what happens, clinically and in patient experience, when someone starts it after a bisphosphonate or stops it and needs a follow-on therapy. It does not cover Xgeva dosing or oncology use.

The core answer

Denosumab's effect on bone turnover is not stored in the skeleton the way a bisphosphonate's is, so stopping it removes the brake on bone resorption within months rather than years. The FDA has issued a safety communication describing an increased risk of spinal fractures, including multiple vertebral fractures, in patients who stop Prolia without moving to another osteoporosis therapy (the FDA has issued a safety communication describing this risk). That is the one claim on this page anchored to a primary regulatory source rather than a forum post or a single trial citation, and it is the reason most osteoporosis specialists now discuss an exit plan before the first dose is given, not after the last one.

What is established, what is plausible, and what is not established

Established, based on the FDA label and the FDA's own safety communication: denosumab reduces fracture risk while a patient remains on schedule, and stopping it without transitioning to another antiresorptive is associated with a real, described risk of rebound vertebral fractures. The FDA label also carries this discontinuation information, and prescribers are expected to plan for it (per the FDA-approved prescribing information).

Plausible but not settled with a precise number, on the evidence available for this page: the magnitude of fracture reduction reported in the pivotal trial, the exact percentage of patients who experience rebound fractures, the exact bone-density gains reported at 10 years, and the specific outcomes of switching to alendronate, zoledronic acid, teriparatide, or romosozumab after denosumab. These figures appear in the published osteoporosis literature and in guideline documents from endocrinology societies, but the specific studies referenced for this draft could not be independently verified against the primary literature at the time of writing. A clinician or medical reviewer should confirm exact figures against the current label and current guideline text before they are published as fixed numbers.

Not established from anything on this page: individual timing of when a given patient's bone turnover will rebound, whether a specific patient needs one bridging infusion or two, and whether online patient-review ratings reflect the actual population of people who take this drug rather than the subset motivated to post.

Why switching matters more with denosumab than with other osteoporosis drugs

Bisphosphonates (alendronate, risedronate, zoledronic acid) bind to bone mineral and continue suppressing resorption for a period after the last dose, which is why a "drug holiday" is sometimes possible with these agents. Denosumab does not work this way. Its RANKL-blocking effect is not stored in bone; it depends on the drug remaining in circulation. When the drug clears, osteoclast activity is not just released back to baseline, it can temporarily overshoot baseline, which is the mechanism generally proposed for the reports of rapid bone density loss and rebound vertebral fractures the FDA describes. This mechanistic explanation is widely cited in the osteoporosis literature and is consistent with the FDA's own description of the risk, but the exact time course (commonly discussed in terms of several months to about a year) should be treated as an approximate clinical pattern rather than a fixed countdown for any individual patient.

Switching to Prolia from an oral bisphosphonate

Patients most often move to denosumab from alendronate or risedronate, usually because of gastrointestinal side effects, dosing burden, or a bone density response that plateaued on oral therapy. Randomized trial data comparing denosumab against continued alendronate in this switching population has been published, and it generally reports numerically greater bone density gains with denosumab over roughly a year of follow-up. The exact percentage-point differences reported in that trial are not repeated here because the specific citation could not be confirmed against the primary source for this draft; a reviewing clinician should pull the current trial report before quoting a precise figure to patients.

Independent of trial data, this is also the direction of switching where patient-reported experience and controlled evidence tend to agree in direction, if not in magnitude: fewer gastrointestinal complaints, less pill burden, and density that generally holds or improves. Online reviews cannot be treated as a dataset (see the section on patient reports below), but the direction of what people describe is not inconsistent with the trial evidence in this specific switching scenario.

What happens if you stop Prolia without a bridging plan

This is the scenario the FDA singled out. After the last injection, bone turnover markers rise, bone density at the spine and hip declines, and case reports and small case series in the literature describe clusters of vertebral fractures occurring in a minority of patients who discontinued denosumab without moving to another antiresorptive, most often within about a year to a year and a half of the last dose. The exact proportion of patients affected varies across the published case series, and this page does not repeat a specific percentage because the underlying study identifiers available for this draft could not be verified. What can be stated plainly, on the strength of the FDA's own communication, is that the risk is real enough that regulators now expect a discontinuation plan to exist before treatment starts, not just when a patient decides to stop.

What bridging therapy usually looks like

Guidance from endocrinology professional societies generally recommends transitioning to a bisphosphonate, most often zoledronic acid or alendronate, either at the time the next denosumab dose would have been due or shortly after, to prevent the rebound rise in bone turnover. A commonly described sequence in osteoporosis clinics is:

1. The last planned denosumab injection is given.
2. Around the time the next dose would have been due, a bisphosphonate (IV zoledronic acid or oral alendronate) is started instead.
3. Bone turnover markers (CTX and P1NP) are checked in the months after the switch to see whether resorption is being controlled.
4. If markers remain elevated, an additional bisphosphonate dose or a different bridging strategy is considered.

The specific guideline documents behind this sequence (AACE/ACE, the Endocrine Society) are real and publicly available, but the exact publication years and recommendation wording cited in earlier drafts of this article could not be confirmed against the primary guideline text and have been removed rather than repeated with unverified precision. Anyone implementing a bridging protocol should confirm the current guideline recommendation directly rather than relying on this summary for dosing decisions.

Switching to an anabolic agent (teriparatide or romosozumab) after denosumab

A smaller group of patients moves from denosumab to an anabolic (bone-building) agent rather than to another antiresorptive. This sequencing is less well studied than denosumab-to-bisphosphonate switching, and the available evidence suggests it behaves differently: transitioning from denosumab directly to teriparatide has been associated with a temporary loss of hip bone density in the first year before gains resume, which is the opposite pattern from what happens when teriparatide is used first and a bisphosphonate follows. Romosozumab after denosumab is not well studied in dedicated trials as of this writing; its use in that sequence is off-guideline and should be understood as site or specialist judgment rather than an established pathway, and insurance coverage for this specific sequence is variable and worth confirming case by case.

What patient reports add, and what they cannot tell you

Online reviews and forum threads about Prolia consistently describe two clusters of experience: people who report meaningful bone density improvement and relief from the gastrointestinal side effects of oral bisphosphonates, and people who describe anxiety about the discontinuation risk, sometimes framed as feeling "trapped" on the drug once they learn about rebound fractures after starting.

Those patterns are worth taking seriously as a signal about communication, not as a measurement of drug performance. Review populations are self-selected toward strong reactions in either direction, sample sizes on any single platform are small relative to the number of patients actually prescribed the drug, and there is no way to confirm from a forum post whether a described bone density change reflects the drug, measurement variability between DEXA scans, or something else entirely. A specific average star rating or exact percentage of reviews mentioning a given complaint is not reported here because no verifiable, citable source for those numbers was available for this draft; treating a scraped review average as a clinical statistic would overstate what it actually shows.

What is more durable, because it does not depend on a specific number, is the recurring theme that some patients say they were not told about discontinuation risk before starting treatment. That theme is consistent with the FDA's decision to issue a dedicated safety communication on the subject, which strongly suggests this was not a rare communication gap.

Who might reasonably stay on denosumab, and who might plan a switch

Patients at very high fracture risk (for example, a T-score in the severe range, a prior vertebral fracture, or ongoing glucocorticoid use) are the group most likely to be advised to continue an antiresorptive like denosumab for an extended period rather than attempt a drug holiday, because the risk of stopping is judged to outweigh the risks of continued treatment for that population. Patients who have reached a bone density target, who face access or cost barriers to continued Prolia, or whose fracture risk has been reassessed as no longer high after several years of treatment are more often the ones for whom clinicians discuss a planned transition to bisphosphonate maintenance. This is a risk-based clinical judgment made with a prescriber, not a decision to make from a review page, and it depends on individual DEXA results, fracture history, and other medications that are outside the scope of this article.

A missed dose is a different problem than a planned switch

If a scheduled Prolia dose is delayed beyond the label's dosing window, bone turnover markers can begin rising before any deliberate discontinuation decision has been made. The immediate priority in that situation is generally to get the overdue dose administered as soon as possible rather than to switch agents mid-cycle, and then to plan any intentional transition later from a position of stable bone turnover. This is a scheduling problem, not the same clinical scenario as a planned stop, and it should be raised with the prescribing clinician promptly rather than managed by guesswork.

Questions worth bringing to your prescriber

• "If I start Prolia, what is the plan for stopping it, and when will we decide that?"
• "What bridging therapy will you use, and how soon after my last dose?"
• "What labs will you check, and when, to confirm the bridge worked?"
• "What is my individual fracture risk category, and does that change the answer?"

If a prescriber does not have a ready answer about an exit strategy, that is a reasonable prompt to ask more questions or seek a second opinion from an endocrinologist or osteoporosis specialist, rather than a reason to stop the drug on your own.

Evidence-strength framework: reported experience versus controlled evidence

Next decision this framework points to: before starting or stopping Prolia, ask your prescriber which row of this table your specific question falls into, and ask them to confirm the exact number (if one is being used to make the decision) against the current FDA label or current specialty guideline rather than a summary page, including this one.

When to seek care sooner rather than later

New or worsening back pain after stopping denosumab, especially in the months following a missed or discontinued dose, warrants prompt evaluation rather than watchful waiting, since it could reflect a new vertebral fracture. Jaw pain, numbness, or exposed bone after dental work should also be reported to a clinician, given the rare but recognized association between long-term antiresorptive therapy and osteonecrosis of the jaw. Thigh or groin pain that develops during long-term treatment should be evaluated for possible atypical femoral fracture. None of this is a substitute for direct evaluation by the prescribing clinician or an emergency provider if symptoms are severe.